Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Follow-up of AAVAnc80-hOTOF Gene Therapy
2024-512584-31-00Phase 3Authorised
- Sponsor
- Akouos
- Start
- Nov 2024
- Modality
- Gene Therapies
- Countries
- 5
01
Overview
Phase 3, open-label, single-arm trial of AK-OTOF in autosomal recessive nonsyndromic deafness 9 (DFNB9) and sensorineural hearing loss (SNHL), sponsored by Akouos. Primary endpoints: Incidence and frequency of adverse events, Concomitant medications and 5 more. Planned start Nov 2024; status: authorised.
02
Drugs
AK-OTOF
03
Conditions
autosomal recessive nonsyndromic deafness 9 (DFNB9)sensorineural hearing loss (SNHL)
Beyond the preview
Go deeper on 2024-512584-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512584-31-00.